Grafalon® (ATLG)
Prophylaxis of acute rejection in organ transplantation; Hematology/Oncology (e.g., stem cell transplantation conditioning)
ApprovedActive
Key Facts
Indication
Prophylaxis of acute rejection in organ transplantation; Hematology/Oncology (e.g., stem cell transplantation conditioning)
Phase
Approved
Status
Active
Company
About Neovii Biotech
Neovii Biotech is a private, commercial-stage biopharmaceutical company specializing in polyclonal antibody therapies for immunosuppression in transplantation and oncology. The company has an established commercial product, Grafalon®, and is led by an experienced management team with backgrounds from major pharmaceutical firms like Roche, Novartis, and Pfizer. Neovii operates with a fully integrated model spanning research, development, and manufacturing, targeting niche but critical areas within the global transplant and hematology markets.
View full company profile